HPN-100 + HPN-100 or Placebo + Placebo + Moxifloxacin + HPN-100 + HPN-100
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Drug Toxicity
Conditions
Drug Toxicity
Trial Timeline
May 1, 2010 → Sep 1, 2010
NCT ID
NCT01135680About HPN-100 + HPN-100 or Placebo + Placebo + Moxifloxacin + HPN-100 + HPN-100
HPN-100 + HPN-100 or Placebo + Placebo + Moxifloxacin + HPN-100 + HPN-100 is a phase 1 stage product being developed by Amgen for Drug Toxicity. The current trial status is completed. This product is registered under clinical trial identifier NCT01135680. Target conditions include Drug Toxicity.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01135680 | Phase 1 | Completed |
Competing Products
20 competing products in Drug Toxicity